IP Library Granted Patent US 7,807,184
Granted Patent B2
US 7,807,184 · App. 10/565,183 · Granted Oct 5, 2010

Hybrid Shiga-like toxin

Assignee: Interuet International B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,184
App. No.
10/565,183
Granted
Oct 5, 2010
Kind
B2
Abstract

The present invention relates to a hybrid bacterial toxin subunit, to a hybrid bipartite bacterial toxin and to nucleic acid molecules comprising a nucleotide sequence encoding such bacterial toxins. Furthermore, the invention relates to vaccines comprising bacterial toxins and to their use in vaccines. Finally, the invention relates to methods for the preparation of such vaccines and to the use of such bacterial toxins for the manufacture of such vaccines.

Claims (11)

1. A hybrid bacterial toxin subunit comprising an A1-part and an A2-part fused together, wherein the A1-part is the A1-part of Shiga-toxin or Shiga-like toxin and the A2-part is the A2-part of Escherichia coli heat-labile enterotoxin.

2. The hybrid bacterial toxin subunit according to claim 1 , wherein the A1-part is the A1-part of Stx2e.

3. A hybrid bipartite bacterial toxin comprising five B-subunits of Escherichia coli heat-labile enterotoxin and the hybrid bacterial toxin subunit according to claim 1 .

4. A vaccine comprising the hybrid bacterial toxin subunit according to claim 1 and a pharmaceutically acceptable carrier.

5. The vaccine according to claim 4 , wherein said vaccine further comprises an additional antigen of a micro-organism pathogenic to animals.

6. The vaccine according to claim 5 , wherein said vaccine comprises Escherichia coli.

7. A method for the preparation of a vaccine, said method comprising the admixing of

the hybrid bacterial toxin subunit according to claim 1 and a pharmaceutically acceptable carrier.

8. The hybrid bipartite bacterial toxin of claim 3 , wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

9. The vaccine of claim 4 , wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

10. The method of claim 7 , wherein the A1-part of the hybrid bacterial toxin subunit is the A1-part of Stx2e.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2006
From: AKZO NOBEL N.V.
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 018490/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2006
From: VERMEIJ, PAUL
To: AKZO NOBEL N.V.
Reel/Frame 017484/0373 →
Priority Claims (1)
EP 03077266 · Jul 21, 2003 · regional
Continuity (1)
Related Publication 20080107653A1 · May 8, 2008